The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Fakeeh University Hospital is emerging as a global destination for advanced gene therapy, delivering highly specialized ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Fakeeh University Hospital is emerging as a global destination for advanced gene therapy, delivering highly specialised ...

Alsayegh, B. , Taso, O. , Dreidi, A. , Alzubi, A. and Alzwaherh, S. (2026) Complicated Gastroschisis with Progressive Fetal ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

X-linked retinoschisis gene replacement therapy, aiming to improve retinal architecture and visual function in young male ...

French pharma major Sanofi (Euronext: SAN) has received a Complete Response Letter (CRL) from the US regulator for ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

Parkinson's disease (PD) is an age-related, progressive, neurodegenerative condition, caused by loss of dopamine-producing neurons. To overcome the shortcomings of conventional levodopa-based ...

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...